Construction of high efficiency retroviral vector for gene therapy of hunter syndrome
US6838280B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2003 |
| Grant date | Jan 4, 2005 |
| Priority date | — |
| Expiry date | Feb 25, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/203
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a retroviral vector containing an iduronate-2-sulfatase (IDS) gene but without selective marker gene, constructed on, as a backbone, a minimum sized MLV-based retroviral vector which does not contain any viral coding sequences but can still produce a high viral titer and drive a high level of gene expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.